Zealand Pharma (CPSE:ZEAL) has drawn fresh attention after reporting that multiple ascending doses of its Kv1.3 blocker ZP9830 were safe and well tolerated in a Phase 1 study of healthy volunteers.
Despite this positive readout, Zealand Pharma’s recent trading tells a different story, with the 30 day share price return down 14.48% and the year to date share price return down 50.18%. At the same time, the 5 year total shareholder return of 8.42% points to much weaker long term momentum than shorter term sentiment shifts might suggest.
Look beyond Zealand Pharma and compare this setup with other healthcare and biotech players on our hand-picked 607 high quality undiscovered gems that have strong fundamentals but remain under the radar.
Zealand Pharma now trades well below the average analyst price target, yet recent weakness and mixed long term returns pull expectations in opposite directions. Where does a reasonable view of fair value actually land?
Most Popular Narrative: 45% Undervalued
On the numbers, the narrative fair value for Zealand Pharma sits at DKK416, compared with a last close of DKK229.20, which places a big gap between where analysts model the business and where the market currently prices it.
The growing focus on combination and multi-mechanism obesity drugs (e.g., amylin plus incretin combinations) and accelerated regulatory pathways for innovative peptides aligns with Zealand's core expertise and pipeline, creating opportunities to capture outsized value from industry investment momentum and delivering upside to projected long-term net income as new products reach market.
See why 28 investors see Zealand Pharma as 45% undervalued.
Result: Fair Value of DKK416 (UNDERVALUED)
Still, the bullish narrative around Zealand Pharma could unravel if key trials like petrelintide or survodutide disappoint, or if obesity competition tightens faster than expected.
Find out about the key risks to this Zealand Pharma narrative.
Next Steps
Mixed messages like this often split opinion on Zealand Pharma, so move quickly, study the data, and weigh both the 1 key reward and 1 important warning sign.
Looking for more investment ideas beyond Zealand Pharma?
If you stop with Zealand Pharma, you miss the bigger picture. Let the data surface fresh opportunities that match your risk tolerance and preferred style.
- Target resilient businesses that combine quality and calm by checking out 229 resilient stocks with low risk scores before market sentiment shifts again.
- Hunt for potential bargains trading below their fundamentals and let the numbers guide you through 191 high quality undervalued stocks while prices still look appealing.
- Build a watchlist of companies with cleaner finances and sturdier funding profiles with the help of the list of solid balance sheet and fundamentals (206 results).
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com